New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

Table 2

Clinical trials evaluating intravitreal corticosteroids for macular edema due to BRVO.

Study	Author/year	Method	Duration	Subjects	Mean BCVA change	Mean CMT change (μm)	Number of injections
ORVO	Campochiaro et al. 2015	Dexamethasone 0.7 mg; (all patients have treated with; anti-VIGF agents before)	16 weeks	17	4 weeks: ~+5.8 (ETDRS); 16 weeks: ~+5.8; (Peak at 4 weeks)	4 weeks: ~−153; 16 weeks: ~−60; (Peak at 4 weeks)	1
SHASTA	Capone et al. [150]	Dexamethasone 0.7 mg	1.2 years	157	~+5.0 (ETDRS)	−154~−188	3.2
SOLO	Bezatis et al. [152]	Dexamethasone 0.7 mg	6 months	54	8 weeks: +0.3 (LogMAR); 24 weeks: +0.15; (Peak at 8 weeks)	8 weeks: −214; 24 weeks: −107; (Peak at 8 weeks)	1.3
GENEVA	Haller et al. [146]	Dexamethasone 0.35 mg/0.7 mg		208	60 days: ~+10.2; (ETDRS); 180 days: ~+6.1	180 days: −103; 360 days: −163	1.85
		Dexamethasone 0.7 mg/0.7 mg	12 months	227	60 days: ~+10.1; 180 days: ~+6.2; 360 days: ~+6.3	180 days: −97; 360 days: −166	1.86
		Sham/0.7 mg (0–6 months/6–12 months)		210	60 days: ~+4.7; 180 days: ~+3.8; 360 days: ~+6.1; (Peak at 60 days)	180 days: −102; 360 days: −170	0.83
SCORE	Ingrid et al. 2009	Triamcinolone 1 mg; Triamcinolone 4 mg; Standard care	12 months	136; 137; 137	+5.7 (ETDRS); +4; +4.2	−245; −250; −312	2.2; 2.1; N/A

Note: only BRVO patients are analyzed in this table. Outcomes are not directly comparable because study design and populations varied from each other. Some studies did not report the accurate number and are estimated by the figures. BRVO: branch retinal vein occlusion; BCVA: best-corrected visual acuity; CMT: central macular thickness; ETDRS: early treatment diabetic retinopathy study; LogMAR: logarithm of the minimum angle of resolution; ORVO: the Ozurdex for retinal vein occlusion study: SHASTA: efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion; SOLO: functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion; GENEVA: sham-controlled randomized trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion; SCORE: the standard care versus corticosteroid for retinal vein occlusion trial.